Fusion Acquisition Corp. II: Nasdaq/NYSE listing notice — Fusion Acquisition Corp. II receives NYSE non-compliance notice for late 2022 10-K; cure deadline Oct 17, 2023

Fusion Acquisition Corp. II

NYSE notified FSNB on April 18, 2023, of non-compliance under Section 802.01E for missing 2022 Form 10-K filing deadline.
NYSE granted a cure period through October 17, 2023; filing the 10-K by then would restore compliance.
The notice has no immediate effect on the listing of FSNB's securities on the NYSE.
Company cited need for additional time to finalize financial statements, as disclosed in Form 12b-25 on March 31, 2023.
FSNB expects to file the 2022 Form 10-K as soon as practicable.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Fusion Acquisition Corp. II received a nyse noncompliance notice notice regarding late filing (rules 802.01E).

Exchange: nyse
Notice: noncompliance notice
Deficiency: late filing
Rules: 802.01E

Exact text from the filing

April 18, 2023, Fusion Acquisition Corp. II (the “ Company ”) received a notice from the New York Stock Exchange (the “ NYSE ”) indicating that the Company is not in compliance with the NYSE’s continued listing requirements under the timely filing criteria set forth in Section 802.01E of the NYSE Listed Company Manual since the Company did not file its Annual Report on Form 10-K for the year ended December 31, 2022 (the “ 2022 Form 10-K ) with the Securities and Exchange Commission (the “ SEC ”) on or before April 17, 2023, the extended period provided for the filing under Rule 12b-25(b) of th

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001213900-23-032067

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.